Lexiva

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

1 competitor in Refractory Gastroesophageal Reflux Disease

#DrugCompanyPhaseTrials

1

Lexiva

GSK

Phase 2

12

Fosamprenavir Calcium

MMedical College of Wisconsin

Phase 2

1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

MPR5 trials

Fosamprenavir Expanded Access

Completed·GSK·Phase 4·NCT00240552·85 enrolled

HCV Evolution in HIV/HCV (Genotype 1) Coinfected Patients Treated With Fosamprenavir

Completed·FFundacion SEIMC-GESIDA·Phase 4·NCT01222611·42 enrolled

Pharmacokinetic Study of Posaconazole Boosted Fosamprenavir

Completed·RRadboud University Medical Center·Phase 1·NCT00817765·24 enrolled

Show 2 more trials

Fosamprenavir Versus Other Protease Inhibitors

Completed·GSK·Phase 3·NCT00094523·314 enrolled

Study to Explore Safety And Tolerability of Fosamprenavir With or Without Ritonavir in Combination With TRIZIVIR or COMBIVIR

Completed·GSK·Phase 3·NCT00043888·60 enrolled

Adult Subject3 trials

An Interaction Study to Assess Drug Levels in Fasting Healthy Adult Subjects

Completed·GGarden State Infectious Disease Associates, PA·N/A·NCT00802074·45 enrolled

An Interaction Study to Assess Drug Levels in Healthy Adult Subjects

Completed·GGarden State Infectious Disease Associates, PA·N/A·NCT00614991·44 enrolled

An Interaction Study to Assess Drug Levels in Healthy Adult Subjects

Completed·GGarden State Infectious Disease Associates, PA·Phase 2·NCT00764465·45 enrolled

Interaction2 trials

GSK1349572 Drug Interaction Study With Fosamprenavir/Ritonavir

Completed·GSK·Phase 1·NCT01209065·27 enrolled

Co-Administration Of Fosamprenavir With Methadone: A Drug Interaction Study.

Completed·GSK·Phase 1·NCT00481182·20 enrolled

HIV-12 trials

Dual Boosted Protease Inhibitor Regimens Without Any Additional Antiretroviral Therapy in HIV-1 Infected Patients (ANRS127)

Completed·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 2·NCT00122603·61 enrolled

A Study To Assess GW433908 (Fosamprenavir) Containing Regimens In HIV-1 Infected Subjects

Completed·GSK·Phase 3·NCT00296504·753 enrolled

Pediatric1 trial

A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2-18 Years

Completed·GSK·Phase 2·NCT00040664·69 enrolled

4 more indications

HIV1 trial

Dual Versus Triple Protease Inhibitor Combinations, Including Ritonavir, in HIV Infected People

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00028366·56 enrolled

Drug Resistance1 trial

Using Drug Levels and Drug Resistance Testing to Select Effective Anti-HIV Drug Combinations in Patients With Drug-resistant HIV

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00027339·53 enrolled

Refractory Gastroesophageal Reflux Disease1 trial

A Phase 2, Randomized, Double-blind, Placebo-controlled Trial of Fosamprenavir Administered Orally for 8 Weeks in Older Adults With Proton Pump Inhibitor Refractory Gastroesophageal Reflux Disease

Not yet recruiting·MMedical College of Wisconsin·Phase 2·NCT06704100·60 enrolled

Unspecified1 trial

KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks

Completed·GSK·Phase 3·NCT00085943·866 enrolled

Regulatory

FDA Approval Timeline[4]

Details

Drug Info

Related News